Evaluation of dual time-point fluorodeoxyglucose PET/computed tomography imaging in gastric cancer

Basit Öğe Kaydı
dc.contributor.authorTasdemir, Bekir
dc.contributor.authorGuzel, Yunus
dc.contributor.authorKomek, Halil
dc.contributor.authorCan, Canan
dc.date.accessioned2024-04-24T17:08:22Z
dc.date.available2024-04-24T17:08:22Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground We aimed to evaluate the efficiency of dual time-point fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging in detecting primary and metastatic lesions in gastric cancer. Methods Between May 2019 and January 2020, 52 patients with gastric carcinoma were prospectively involved in our study. And dual time-point FDG PET/CT imaging performed to the patients. Of detected primary and metastatic lesions, the ones that are better visualized or only appear in delayed imaging were visually identified. Also, maximum standardized uptake value (SUVmax) of the primary and metastatic lesions and the intact liver tissue were measured in early and delayed imaging. Acquired SUVmax values and SUVmax ratios were compared statistically. Results In delayed images, lesions were better visualized in 32 patients (61.5%) and extra lesions were detected in 4 patients (7.7%). SUVmax of primary tumor, SUVmax of liver metastases, SUVmax of lymph node metastases, primary tumor SUVmax/liver SUVmax ratio and lymph node metastasis SUVmax/liver SUVmax ratio were significantly higher in delayed images (P < 0.001, P = 0.022, P < 0.001, P < 0.001, P < 0.001, respectively). However, SUVmax of liver parenchyma was significantly lower in delayed images (P < 0.001). Conclusions There is a visually and statistically significant increase in the number and detectability of lesions seen in delayed images and dual time-point FDG PET/CT imaging seems useful in detecting primary and metastatic lesions in gastric cancer.en_US
dc.identifier.doi10.1097/MNM.0000000000001290
dc.identifier.endpage1327en_US
dc.identifier.issn0143-3636
dc.identifier.issn1473-5628
dc.identifier.issue12en_US
dc.identifier.pmid32956249
dc.identifier.scopus2-s2.0-85096151652
dc.identifier.scopusqualityQ3
dc.identifier.startpage1322en_US
dc.identifier.urihttps://doi.org/10.1097/MNM.0000000000001290
dc.identifier.urihttps://hdl.handle.net/11468/17317
dc.identifier.volume41en_US
dc.identifier.wosWOS:000589817400014
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofNuclear Medicine Communications
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDual-Time-Point Imagingen_US
dc.subjectFluorine-18 Fluorodeoxyglucose Peten_US
dc.subjectComputed Tomographyen_US
dc.subjectGastric Canceren_US
dc.titleEvaluation of dual time-point fluorodeoxyglucose PET/computed tomography imaging in gastric canceren_US
dc.titleEvaluation of dual time-point fluorodeoxyglucose PET/computed tomography imaging in gastric cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu